Benign and malignant hematological manifestations of chronic hepatitis C virus infection

Shiksha Kedia, Vijaya Raj Bhatt, Sandeep Rajan, Pavan Kumar Tandra, Radwa A. El Behery, Mojtaba Akhtari

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Chronic hepatitis C virus (HCV) infection, that affects 3% of world’s population, is associated with several hematological manifestations mainly benign cytopenias, coagulopathy and lymphoproliferative diseases. Immune or non-immune-mediated thrombocytopenia is a major challenge in chronic HCV infected patients especially in the setting of an advanced liver disease, with average prevalence of nearly 24%. Although several treatment modalities such as steroids, intravenous immunoglobulin, splenectomy and immunosuppresants have been tried with some success, their efficacy is not impressive and can result in an increase in viral load or other thrombotic complications. Even though a recent phase 2 study has shown promising role of a platelet growth factor, eltrombopag, in boosting platelets counts prior to antiviral treatment, its use in pre-operative setting had unexpected complications. Unlike thrombocytopenia, anemia and neutropenia are more frequently seen in treated patients and are often the result of antiviral therapy. HCV infection also pre-disposes to lymphoproliferative diseases, mainly non-Hodking’s lymphomas, likely as a result of chronic antigenic stimulation and mutation of several genes involved in carcinogenesis. Understanding of the role of HCV infection in these conditions has therapeutic implications. Whereas antiviral therapy has shown therapeutic role in HCV-associated indolent lymphomas, monitoring of hepatic function and viral load is important in the management of diffuse large B-cell lymphoma in HCV-infected patients. Although our knowledge about the HCV infection and hematological manifestations has substantially grown in last few decades, further studies are important to advance our therapeutic approach.

Original languageEnglish (US)
Pages (from-to)179-192
Number of pages14
JournalInternational Journal of Preventive Medicine
Volume2014
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Virus Diseases
Hepacivirus
Antiviral Agents
Viral Load
Thrombocytopenia
Therapeutics
Lymphoma
Lymphoma, Large B-Cell, Diffuse
Intravenous Immunoglobulins
Splenectomy
Neutropenia
Platelet Count
Liver Diseases
Anemia
Intercellular Signaling Peptides and Proteins
Carcinogenesis
Blood Platelets
Steroids
Mutation

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health

Cite this

Kedia, S., Bhatt, V. R., Rajan, S., Tandra, P. K., El Behery, R. A., & Akhtari, M. (2014). Benign and malignant hematological manifestations of chronic hepatitis C virus infection. International Journal of Preventive Medicine, 2014, 179-192.

Benign and malignant hematological manifestations of chronic hepatitis C virus infection. / Kedia, Shiksha; Bhatt, Vijaya Raj; Rajan, Sandeep; Tandra, Pavan Kumar; El Behery, Radwa A.; Akhtari, Mojtaba.

In: International Journal of Preventive Medicine, Vol. 2014, 01.12.2014, p. 179-192.

Research output: Contribution to journalReview article

Kedia, S, Bhatt, VR, Rajan, S, Tandra, PK, El Behery, RA & Akhtari, M 2014, 'Benign and malignant hematological manifestations of chronic hepatitis C virus infection', International Journal of Preventive Medicine, vol. 2014, pp. 179-192.
Kedia, Shiksha ; Bhatt, Vijaya Raj ; Rajan, Sandeep ; Tandra, Pavan Kumar ; El Behery, Radwa A. ; Akhtari, Mojtaba. / Benign and malignant hematological manifestations of chronic hepatitis C virus infection. In: International Journal of Preventive Medicine. 2014 ; Vol. 2014. pp. 179-192.
@article{ecb28b2d288c4b4f99e64a39c8aa3b04,
title = "Benign and malignant hematological manifestations of chronic hepatitis C virus infection",
abstract = "Chronic hepatitis C virus (HCV) infection, that affects 3{\%} of world’s population, is associated with several hematological manifestations mainly benign cytopenias, coagulopathy and lymphoproliferative diseases. Immune or non-immune-mediated thrombocytopenia is a major challenge in chronic HCV infected patients especially in the setting of an advanced liver disease, with average prevalence of nearly 24{\%}. Although several treatment modalities such as steroids, intravenous immunoglobulin, splenectomy and immunosuppresants have been tried with some success, their efficacy is not impressive and can result in an increase in viral load or other thrombotic complications. Even though a recent phase 2 study has shown promising role of a platelet growth factor, eltrombopag, in boosting platelets counts prior to antiviral treatment, its use in pre-operative setting had unexpected complications. Unlike thrombocytopenia, anemia and neutropenia are more frequently seen in treated patients and are often the result of antiviral therapy. HCV infection also pre-disposes to lymphoproliferative diseases, mainly non-Hodking’s lymphomas, likely as a result of chronic antigenic stimulation and mutation of several genes involved in carcinogenesis. Understanding of the role of HCV infection in these conditions has therapeutic implications. Whereas antiviral therapy has shown therapeutic role in HCV-associated indolent lymphomas, monitoring of hepatic function and viral load is important in the management of diffuse large B-cell lymphoma in HCV-infected patients. Although our knowledge about the HCV infection and hematological manifestations has substantially grown in last few decades, further studies are important to advance our therapeutic approach.",
author = "Shiksha Kedia and Bhatt, {Vijaya Raj} and Sandeep Rajan and Tandra, {Pavan Kumar} and {El Behery}, {Radwa A.} and Mojtaba Akhtari",
year = "2014",
month = "12",
day = "1",
language = "English (US)",
volume = "2014",
pages = "179--192",
journal = "International Journal of Preventive Medicine",
issn = "2008-7802",
publisher = "Isfahan University of Medical Sciences(IUMS)",

}

TY - JOUR

T1 - Benign and malignant hematological manifestations of chronic hepatitis C virus infection

AU - Kedia, Shiksha

AU - Bhatt, Vijaya Raj

AU - Rajan, Sandeep

AU - Tandra, Pavan Kumar

AU - El Behery, Radwa A.

AU - Akhtari, Mojtaba

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Chronic hepatitis C virus (HCV) infection, that affects 3% of world’s population, is associated with several hematological manifestations mainly benign cytopenias, coagulopathy and lymphoproliferative diseases. Immune or non-immune-mediated thrombocytopenia is a major challenge in chronic HCV infected patients especially in the setting of an advanced liver disease, with average prevalence of nearly 24%. Although several treatment modalities such as steroids, intravenous immunoglobulin, splenectomy and immunosuppresants have been tried with some success, their efficacy is not impressive and can result in an increase in viral load or other thrombotic complications. Even though a recent phase 2 study has shown promising role of a platelet growth factor, eltrombopag, in boosting platelets counts prior to antiviral treatment, its use in pre-operative setting had unexpected complications. Unlike thrombocytopenia, anemia and neutropenia are more frequently seen in treated patients and are often the result of antiviral therapy. HCV infection also pre-disposes to lymphoproliferative diseases, mainly non-Hodking’s lymphomas, likely as a result of chronic antigenic stimulation and mutation of several genes involved in carcinogenesis. Understanding of the role of HCV infection in these conditions has therapeutic implications. Whereas antiviral therapy has shown therapeutic role in HCV-associated indolent lymphomas, monitoring of hepatic function and viral load is important in the management of diffuse large B-cell lymphoma in HCV-infected patients. Although our knowledge about the HCV infection and hematological manifestations has substantially grown in last few decades, further studies are important to advance our therapeutic approach.

AB - Chronic hepatitis C virus (HCV) infection, that affects 3% of world’s population, is associated with several hematological manifestations mainly benign cytopenias, coagulopathy and lymphoproliferative diseases. Immune or non-immune-mediated thrombocytopenia is a major challenge in chronic HCV infected patients especially in the setting of an advanced liver disease, with average prevalence of nearly 24%. Although several treatment modalities such as steroids, intravenous immunoglobulin, splenectomy and immunosuppresants have been tried with some success, their efficacy is not impressive and can result in an increase in viral load or other thrombotic complications. Even though a recent phase 2 study has shown promising role of a platelet growth factor, eltrombopag, in boosting platelets counts prior to antiviral treatment, its use in pre-operative setting had unexpected complications. Unlike thrombocytopenia, anemia and neutropenia are more frequently seen in treated patients and are often the result of antiviral therapy. HCV infection also pre-disposes to lymphoproliferative diseases, mainly non-Hodking’s lymphomas, likely as a result of chronic antigenic stimulation and mutation of several genes involved in carcinogenesis. Understanding of the role of HCV infection in these conditions has therapeutic implications. Whereas antiviral therapy has shown therapeutic role in HCV-associated indolent lymphomas, monitoring of hepatic function and viral load is important in the management of diffuse large B-cell lymphoma in HCV-infected patients. Although our knowledge about the HCV infection and hematological manifestations has substantially grown in last few decades, further studies are important to advance our therapeutic approach.

UR - http://www.scopus.com/inward/record.url?scp=84944457873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944457873&partnerID=8YFLogxK

M3 - Review article

VL - 2014

SP - 179

EP - 192

JO - International Journal of Preventive Medicine

JF - International Journal of Preventive Medicine

SN - 2008-7802

ER -